Denali sells FDA voucher for $195M to support neurodegenerative pipeline
Denali Therapeutics is the latest company to sell a priority review fast pass for an elevated price after the program was renewed earlier this year.
Denali Therapeutics
Profile of Denali Therapeutics created from news harvest. To be enriched by user.
Company Info
Clinical Development Pipeline
Undisclosed
Target: TBDRecent News
Leadership Team
To be confirmed
Chief Executive Officer
To be confirmed
Chief Medical Officer
To be confirmed
Chief Scientific Officer
Careers & Job Openings